Lodoco is a drug owned by Agepha Pharma Fz Llc. It is protected by 11 US drug patents filed from 2023 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 09, 2034. Details of Lodoco's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10130585 | Methods of treating and/or preventing cardiovascular disease |
May, 2034
(8 years from now) | Active |
| US11026901 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(8 years from now) | Active |
| US11026900 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(8 years from now) | Active |
| US11026899 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(8 years from now) | Active |
| US10842762 | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Nov, 2033
(8 years from now) | Active |
| US10265281 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(8 years from now) | Active |
| US10206891 | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Nov, 2033
(8 years from now) | Active |
| US9744144 | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Nov, 2033
(8 years from now) | Active |
| US11944594 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(8 years from now) | Active |
| US12233035 | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent and statin |
Nov, 2033
(8 years from now) | Active |
| US11944595 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lodoco's patents.
Latest Legal Activities on Lodoco's Patents
Given below is the list of recent legal activities going on the following patents of Lodoco.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 07 May, 2024 | US10842762 |
| Recordation of Patent Grant Mailed Critical | 02 Apr, 2024 | US11944594 |
| Recordation of Patent eGrant | 02 Apr, 2024 | US11944594 |
| Email Notification Critical | 02 Apr, 2024 | US11944595 |
| Mail Patent eGrant Notification | 02 Apr, 2024 | US11944595 |
| Mail Patent eGrant Notification | 02 Apr, 2024 | US11944594 |
| Patent Issue Date Used in PTA Calculation Critical | 02 Apr, 2024 | US11944594 |
| Email Notification Critical | 02 Apr, 2024 | US11944594 |
| Patent eGrant Notification | 02 Apr, 2024 | US11944594 |
| Patent eGrant Notification | 02 Apr, 2024 | US11944595 |
US patents provide insights into the exclusivity only within the United States, but Lodoco is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lodoco's family patents as well as insights into ongoing legal events on those patents.
Lodoco's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lodoco's generic launch date based on the expiry of its last outstanding patent is estimated to be May 09, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lodoco Generic API suppliers:
Colchicine is the generic name for the brand Lodoco. 12 different companies have already filed for the generic of Lodoco, with Zydus Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lodoco's generic
Alternative Brands for Lodoco
Lodoco which is used for treating and reducing the risk of cardiovascular events, acute myocardial infarction, atherosclerotic vascular disease, and inflammation., has several other brand drugs using the same active ingredient (Colchicine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Colchicine, Lodoco's active ingredient. Check the complete list of approved generic manufacturers for Lodoco
About Lodoco
Lodoco is a drug owned by Agepha Pharma Fz Llc. It is used for treating and reducing the risk of cardiovascular events, acute myocardial infarction, atherosclerotic vascular disease, and inflammation. Lodoco uses Colchicine as an active ingredient. Lodoco was launched by Agepha Pharma Fz in 2023.
Approval Date:
Lodoco was approved by FDA for market use on 16 June, 2023.
Active Ingredient:
Lodoco uses Colchicine as the active ingredient. Check out other Drugs and Companies using Colchicine ingredient
Treatment:
Lodoco is used for treating and reducing the risk of cardiovascular events, acute myocardial infarction, atherosclerotic vascular disease, and inflammation.
Dosage:
Lodoco is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.5MG | TABLET | Prescription | ORAL |